BioCentury | Aug 3, 2018
Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
BioCentury | Jul 11, 2016
Company News

Eleven Biotherapeutics ophthalmic news

Eleven Biotherapeutics said it will reduce headcount by 14 (70%) to about six. This month, FDA approved an IND for EBI-031 to treat ocular diseases, such as diabetic macular edema (DME). In June, the company...
BioCentury | Mar 5, 2015
Tools & Techniques

Nixing antibody aggregation

...used at AnaptysBio - are less prone to aggregation than antibodies derived from phage- and yeast-display systems...
BioCentury | Feb 26, 2015
Tools & Techniques

The Power of Two

The goal of chemical libraries is to contain enough molecules that even targets with uncommon binding sites can find the rare compound that binds with high affinity. Rather than synthesizing hundreds of thousands of molecules,...
BioCentury | Feb 26, 2015
Distillery Techniques

Techniques: Therapeutic bispecific κλ-bodies

Drug platforms TECHNOLOGY: Antibody scaffolds In vitro studies have identified a method for developing κλ-bodies, which are bispecific human mAbs that could be useful as therapeutics. The κλ-bodies were generated on an in vitro display...
BioCentury | Sep 18, 2014
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Programmable ligand display system to identify multivalent binders to GPCRs A programmable ligand-display system could be useful for identifying high-affinity compounds that bind GPCR...
BioCentury | May 8, 2014
Strategy

Temple building

The Temple University School of Pharmacy has teamed up with MorphoSys AG to bring industry-quality antibody technology in-house. The partnership expands MorphoSys' access to early stage research and adds to the toolkit of discovery capabilities...
BioCentury | Jul 11, 2013
Distillery Techniques

Technology: Drug platforms

...difficult step for in vitro antibody discovery is the cloning of candidates discovered via bacterial display systems...
BioCentury | Jun 13, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Phage display system for rapid mammalian expression of library hits A phage display system designed to facilitate expression in mammalian cells...
BioCentury | Jul 4, 2011
Company News

U.S. Patent and Trademark Office other news

The U.S. Supreme Court will hear Kappos v. Hyatt to decide whether a plaintiff in a Section 145 action can introduce new evidence that could have been presented to the PTO upon the initial filing...
Items per page:
1 - 10 of 30
BioCentury | Aug 3, 2018
Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
BioCentury | Jul 11, 2016
Company News

Eleven Biotherapeutics ophthalmic news

Eleven Biotherapeutics said it will reduce headcount by 14 (70%) to about six. This month, FDA approved an IND for EBI-031 to treat ocular diseases, such as diabetic macular edema (DME). In June, the company...
BioCentury | Mar 5, 2015
Tools & Techniques

Nixing antibody aggregation

...used at AnaptysBio - are less prone to aggregation than antibodies derived from phage- and yeast-display systems...
BioCentury | Feb 26, 2015
Tools & Techniques

The Power of Two

The goal of chemical libraries is to contain enough molecules that even targets with uncommon binding sites can find the rare compound that binds with high affinity. Rather than synthesizing hundreds of thousands of molecules,...
BioCentury | Feb 26, 2015
Distillery Techniques

Techniques: Therapeutic bispecific κλ-bodies

Drug platforms TECHNOLOGY: Antibody scaffolds In vitro studies have identified a method for developing κλ-bodies, which are bispecific human mAbs that could be useful as therapeutics. The κλ-bodies were generated on an in vitro display...
BioCentury | Sep 18, 2014
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Programmable ligand display system to identify multivalent binders to GPCRs A programmable ligand-display system could be useful for identifying high-affinity compounds that bind GPCR...
BioCentury | May 8, 2014
Strategy

Temple building

The Temple University School of Pharmacy has teamed up with MorphoSys AG to bring industry-quality antibody technology in-house. The partnership expands MorphoSys' access to early stage research and adds to the toolkit of discovery capabilities...
BioCentury | Jul 11, 2013
Distillery Techniques

Technology: Drug platforms

...difficult step for in vitro antibody discovery is the cloning of candidates discovered via bacterial display systems...
BioCentury | Jun 13, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Phage display system for rapid mammalian expression of library hits A phage display system designed to facilitate expression in mammalian cells...
BioCentury | Jul 4, 2011
Company News

U.S. Patent and Trademark Office other news

The U.S. Supreme Court will hear Kappos v. Hyatt to decide whether a plaintiff in a Section 145 action can introduce new evidence that could have been presented to the PTO upon the initial filing...
Items per page:
1 - 10 of 30